非小细胞肺癌患者血清SAA、IGF-1、TIMP-1水平与病理特征及预后的相关性

Correlation of Serum SAA, IGF-1, and TIMP-1 Levels with Pathological Features and Prognosis in Patients with Non-small Cell Lung Cancer

摘要

目的 探讨血清淀粉样蛋白A（SAA）、胰岛素样生长因子-1（IGF-1）、金属蛋白酶抑制剂-1（TIMP-1）与非小细胞肺癌病理特征及预后的相关性。方法 选取2021年3月~2023年7月就诊于商丘市立医院的84例非小细胞肺癌患者为研究组,根据不同预后分为预后不良及预后良好患者,另选取本院同期收治的80例良性肺部病变患者作为对照组。对比2组入院时血清SAA、IGF-1、TIMP-1水平;对比非小细胞肺癌患者不同病理学参数及不同预后患者入院时血清各指标水平;ROC分析非小细胞肺癌患者入院时血清各指标水平联合检测对预后不良的预测价值。结果 研究组血清SAA、IGF-1、TIMP-1水平显著高于对照组（P<0.05）;不同病理学参数非小细胞肺癌患者血清SAA、IGF-1、TIMP-1水平比较：Ⅰ~Ⅱ期低于Ⅲ~Ⅳ期、无淋巴结转移低于有淋巴结转移（P<0.05）;预后不良患者血清SAA、IGF-1、TIMP-1水平显著高于预后良好患者（P<0.05）;入院时联合检测血清SAA、IGF-1、TIMP-1水平对非小细胞肺癌预后不良的预测价值较高。结论 非小细胞肺癌患者中血清SAA、IGF-1、TIMP-1的表达与患者病理特征及预后相关,检测其表达对判断患者病情程度及评估预后具有重要价值。

Abstract

Objective To investigate the correlation between serum amyloid A (SAA), insulin-like growth factor-1 (IGF-1), and tissue inhibitor of metalloproteinase-1 (TIMP-1) and the pathological characteristics and prognosis of non-small cell lung cancer. Methods Eighty-four cases of non-small cell lung cancer patients who attended Shangqiu Municipal Hospital from March 2021 to July 2023 were selected as the study group, which were categorized into patients with poor and good prognosis according to different prognoses, and 80 cases of benign lung lesions admitted to the same hospital during the same period were selected as the control group. The levels of serum SAA, IGF-1 and TIMP-1 at the time of admission were compared between the two groups; the levels of serum indicators at the time of admission were compared between non-small cell lung cancer patients with different pathologic parameters and patients with different prognoses. ROC was used to analyze the predictive value of poor prognosis of non-small cell lung cancer patients by the combined detection of serum levels of various indexes at the time of admission. Results The levels of SAA, IGF-1 and TIMP-1 of the study group were significantly higher than those in the control group (P< 0.05). The levels of SAA, IGF-1 and TIMP-1 in patients with non-small cell lung cancer with different pathological parameters were lower in stages Ⅰ and Ⅱ than in stages Ⅲ and Ⅳ, and no lymph node metastasis was lower than having lymph node metastasis (P<0.05). Serum levels of SAA, IGF-1 and TIMP-1 in patients with poor prognosis were significantly higher than those in patients with good prognosis (P<0.05). The combined detection of serum SAA, IGF-1 and TIMP-1 levels on admission had high predictive value for poor prognosis of NSCLC. Conclusion The expression of serum SAA, IGF-1, and TIMP-1 in patients with non-small cell lung cancer is associated with their pathological characteristics and prognosis, and the detection of its expression is of great value in determining the degree of the patient's condition and evaluating the prognosis.

关键词

非小细胞肺癌 / SAA / IGF-1 / TIMP-1 / 预后

Key words

Non-small cell lung cancer / SAA / IGF-1 / TIMP-1 / Prognosis

[1] 焦兰晨,王可铮. PET/CT预测非小细胞肺癌PD-1/PD-L1表达及免疫治疗评估中的价值[J]. 中国肿瘤,2022,31(8):672-678.
[2] Aoki MN, Amarante MK, de Oliveira CEC, et al. Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy[J]. Anticancer Agents Med Chem, 2018, 18(15): 2070-2077.
[3] 钟萍,张军,凌华. 非小细胞肺癌患者血清CA125、TIMP-1、SAA水平与临床病理特征和预后的关系[J]. 临床肺科杂志,2022,27(9):1411-1415.
[4] 闫明,程纪伟,孙海波,等. 非小细胞肺癌中IGF1、IGFBP2表达与预后的相关性分析[J]. 临床肺科杂志,2022,27(1):78-82.
[5] 赵景景,谭于飞,李玲,等. 吉非替尼对老年晚期EGFR突变型非小细胞肺癌的疗效及对MMP-9、TIMP-1水平的影响[J]. 实用癌症杂志,2023,38(1):156-159.
[6] Ettinger DS, Wood DE, Aggarwal C, et al.NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1. 2020[J]. J Natl Compr Canc Netw, 2019, 17(12): 1464-1472.
[7] 刘延国,王秀问,刘联. 晚期非小细胞肺癌免疫治疗应用时长之思辨[J]. 中华医学杂志,2022,102(22):1691-1698.
[8] Sreedurgalakshmi K, Srikar R, Rajkumari R.CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries[J]. Cancer Gene Ther, 2021, 28(6): 566-580.
[9] 雷艳,张革红. 生物标志物在晚期非小细胞肺癌免疫治疗中的预测价值[J]. 国际肿瘤学杂志,2022,49(12):739-744.
[10] 张新燕,刘英香,赵国栋. 结直肠癌中SAA2表达与肿瘤免疫微环境的关系[J]. 中国免疫学杂志,2022,38(20):2495-2500.
[11] 饶汕,李森. 肺癌患者中血清NSE、ProGRP、SAA的表达及与临床病理特征的关系[J]. 检验医学与临床,2022,19(4):463-466.
[12] 欧阳长理,李智勇,李洪春. IGF-1、IGFBP-3在非小细胞肺癌血清和组织中的表达及临床意义[J]. 临床肿瘤学杂志,2022,27(6):522-526.
[13] 褚来利,韩亚民,李林. 非小细胞肺癌患者胰岛素样生长因子1受体、可溶性B7-H4的表达及临床意义[J]. 实用医院临床杂志,2022,19(5):128-130.
[14] 王晓建,袁洋,王博. 细胞间黏附分子-1、基质金属蛋白酶9及基质金属蛋白酶组织抑制物-1在非小细胞肺癌中的表达及与患者临床特征的关系[J]. 癌症进展,2023,21(5):553-556.
[15] 李佳,曾庆华. MSCT检查联合血清MMP-9、TIMP-1检测对肺癌的诊断价值[J]. 山东医药,2019,59(13):65-67.